Industry Experts

Victor Goldmacher, PhD has over 30 years of experience in targeted cancer therapeutics, antibody technologies, and apoptosis biology. After earning his degree from Moscow State University and completing postdoctoral training at MIT, he joined Dana-Farber Cancer Institute, later becoming a founding scientist at ImmunoGen, Inc., where he led Cell Biology and contributed to the discovery of three FDA-approved drugs, Kadcyla, Sarclisa, and Elahere, and two cytomegalovirus cell-death suppressors. Following leadership roles at Forbius (acquired by BMS), he now serves as Chief Scientific Officer at ImmuVia, Inc., developing bispecific antibodies that target tumor antigens and Death Receptor 5 to induce apoptosis in cancer cells.